RIPK1 Inhibitors Match Placebo Safety in Human Clinical Trials
A systematic review of 16 clinical trials found that receptor-interacting protein kinase 1 inhibitors showed adverse event risks comparable to placebos while successfully reaching high target inhibition.
FTMQ Health, written by our newsroom0 views
A systematic review and meta-analysis published in Cell Death Discovery found that receptor-interacting protein kinase 1 inhibitors do not increase adverse event risks compared to a placebo, Bioengineer.org reported. The study evaluated data across 16 clinical trials involving human patients and healthy volunteers. [1]
The pooled analysis evaluated the therapeutic safety, pharmacokinetic behavior, and pharmacodynamic effects of the RIPK1 inhibitor class in humans. Bioengineer.org reported that participants taking the inhibitors showed an incidence of adverse events comparable to those receiving a placebo, yielding an overall pooled risk ratio of 0.99. [1]
Researchers observed that RIPK1 inhibitors achieved up to 97 percent target inhibition in the randomized placebo-controlled trials, according to Bioengineer.org. The findings offer practical context on the drug class for potential use in treating inflammatory conditions. [1]
Chronic inflammatory demyelinating polyneuropathy is one example of an autoimmune condition involving peripheral nervous system damage. The disease causes progressive weakness alongside sensory impairment in the arms and legs. [2]
In short
- A systematic review analyzed data from 16 clinical trials evaluating RIPK1 inhibitors.
- RIPK1 inhibitors achieved up to 97 percent target inhibition in human trials.
- The overall pooled risk ratio for adverse events between RIPK1 inhibitors and placebos was 0.99.
Sources
Every paragraph above points to the numbered items it rests on. Read the originals here.
- [1]RIPK1 Inhibitors Match Placebo Safety in Human Inflammatory Disease TrialsBioengineer.org, 2d ago (the report this story comes from)
Background
- [2]Chronic inflammatory demyelinating polyneuropathy on Wikipedia
Our newsroom writes these reports with the help of software, from the 2 sources listed and nothing else, and checks them against those sources. Facts can still be wrong or move on; the originals are the record. Spotted a mistake? Write to daniel@monsterkong.com.
Related from FTMQ Health
Earlier reports of ours on the same people and subjects.
- CAR T cell therapy analysis reveals high inflammation but low mortalityMedical Science, 4h ago
- Targeting the P2X7 receptor reduces harmful human brain inflammationFitness, 41d ago
- Study links specific ultra processed foods to bowel cancer riskNutrition, 33d ago
- Physical activity improves mood and quality of life during menopauseFitness, 31d ago
- Stopping GLP1 receptor agonist treatment increases stroke and heart attack riskHealth Care, 6d ago
More in Medical Science
- CAR T cell therapy analysis reveals high inflammation but low mortality4h ago
- Diets rich in dairy and fruit linked to child height growth1d ago
- Meningococcal B vaccine prompts immune responses against gonorrhea in trial2d ago
- Frontiers in Psychiatry collection highlights music interventions for mental health3d ago
- Shanghai dismisses researchers after gene editing trial death3d ago
- Trial in Mali tests azithromycin impacts on infant antimicrobial resistance4d ago
Get the day in one email
Reports like this one, the top news of the last 24 hours, every morning. Free, one email a day; readers can comment under every report.
By signing up you agree to our terms and privacy policy. Unsubscribe any time.

Comments
Loading
Join the conversation
Comments are open to readers of our daily email: the top news of the last 24 hours, every morning, free. Sign up and the comment box opens.
Already on the list? Enter the same address and we will send a sign-in link.
By signing up you agree to our terms and privacy policy. Unsubscribe any time.